Caterina Nardella

Caterina Nardella

Auto-generated profile, based on publicly available information

Caterina Nardella

Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2008 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ACArkaitz Carracedo
Arkaitz Carracedo
LMLi Ma
Li Ma
JTJulie Teruya-Feldstein
Julie Teruya-Feldstein
FRFederico Rojo
Federico Rojo
LSLeonardo Salmena
Leonardo Salmena
PPPier Paolo Pandolfi
Pier Paolo Pandolfi
Numerous studies have established a causal link between aberrant mammalian target of rapamycin (mTOR) activation and tumorigenesis, indicating that mTOR inhibition may have therapeutic potential. In this study, we show that rapamycin and its analogs activate the MAPK pathway in human cancer, in what represents a novel mTORC1-MAPK feedback loop. We found that tumor samples from patients with biopsy-accessible solid tumors of advanced disease treated with RAD001, a rapamycin derivative, showed an administration schedule–dependent increase in activation of the MAPK pathway. RAD001 treatment also led to MAPK activation in a mouse model of prostate cancer. We further show that rapamycin-induced MAPK activation occurs in both normal cells and cancer cells lines and that this feedback loop depends on an S6K-PI3K-Ras pathway. Significantly, pharmacological inhibition of the MAPK pathway enhanced the antitumoral effect of mTORC1 inhibition by rapamycin in cancer cells in vitro and in a xenograft mouse model. Taken together, our findings identify MAPK activation as a consequence of mTORC1 inhibition and underscore the potential of a combined therapeutic approach with mTORC1 and MAPK inhibitors, currently employed as single agents in the clinic, for the treatment of human cancers.

26 April 2009 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
BCBrett S Carver
Brett S Carver
JTJennifer Tran
Jennifer Tran
AGAnuradha Gopalan
Anuradha Gopalan
ZCZhenbang Chen
Zhenbang Chen
SSSafa Shaikh
Safa Shaikh
PPPier Paolo Pandolfi
Pier Paolo Pandolfi

18 April 2010 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
AAAndrea Alimonti
Andrea Alimonti
ACArkaitz Carracedo
Arkaitz Carracedo
JCJohn G Clohessy
John G Clohessy
LTLloyd C Trotman
Lloyd C Trotman
CNCaterina Nardella
Caterina Nardella
PPPier Paolo Pandolfi
Pier Paolo Pandolfi

24 June 2011 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
CNCaterina Nardella
Caterina Nardella
JCJohn G Clohessy
John G Clohessy
AAAndrea Alimonti
Andrea Alimonti
PPPier Paolo Pandolfi
Pier Paolo Pandolfi

1 November 2012 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
AJAshish Juvekar
Ashish Juvekar
LBLaura N. Burga
Laura N. Burga
HHHai Hu
Hai Hu
ELElaine P. Lunsford
Elaine P. Lunsford
YIYasir H. Ibrahim
Yasir H. Ibrahim
GWGerburg Wulf
Gerburg Wulf
There is a need to improve treatments for metastatic breast cancer. Here, we show the activation of the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways in a MMTV-CreBrca1f/fTrp53+/− mouse model of breast cancer. When treated with the pan-class IA PI3K inhibitor NVP-BKM120, tumor doubling was delayed from 5 to 26 days. NVP-BKM120 reduced AKT phosphorylation, tumor cell proliferation, and angiogenesis. Resistant tumors maintained suppression of AKT phosphorylation but exhibited activation of the MAPK pathway at the “pushing margin.” Surprisingly, PI3K inhibition increased indicators of DNA damage, poly-ADP-ribosylation (PAR), and γ-H2AX, but decreased Rad51 focus formation, suggesting a critical role of PI3K activity for Rad51 recruitment. The PARP inhibitor olaparib alone attenuated tumor growth modestly; however, the combination of NVP-BKM120 and olaparib delayed tumor doubling to more than 70 days in the mouse model and more than 50 days in xenotransplants from human BRCA1-related tumors, suggesting that combined PI3K and PARP inhibition might be an effective treatment of BRCA1-related tumors. Significance: Current treatment options for triple-negative breast cancer are limited to chemotherapeutic regimens that have considerable toxicity and are not curative. We report here that the combination of a PI3K inhibitor with a PARP inhibitor provides in vivo synergy for treatment of an endogenous mouse model for BRCA1-related breast cancers, making this a candidate combination to be tested in human clinical trials. Cancer Discov; 2(11); 1048–63. ©2012 AACR. Read the Commentary on this article by Rehman et al., p. 982. This article is highlighted in the In This Issue feature, p. 961

18 March 2010 in Nature
Verified
Journal Article
Closed access
PDF file
HLHui-Kuan Lin
Hui-Kuan Lin
ZCZhenbang Chen
Zhenbang Chen
GWGuocan Wang
Guocan Wang
CNCaterina Nardella
Caterina Nardella
SLSzu-Wei Lee
Szu-Wei Lee
PPPier Paolo Pandolfi
Pier Paolo Pandolfi